Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Safety and PK of Topical PF-07038124 in Healthy Volunteers
NCT04135560Phase 1Completed
- Sponsor
- Pfizer
- Start
- Oct 2019
- Primary completion
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PF-07038124 in atopic dermatitis (AD) (7 arms), sponsored by Pfizer. Primary endpoints: Treatment Emergent Treatment-Related Adverse Events at 41 days and Adverse Events by Severity at 41 days. Started Oct 2019; status: completed.
02
Drugs
PF-07038124
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT04135560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04135560.